Related Experiment Videos
Colon interposition: an adjuvant operation for short-gut syndrome
Insights
Colon interposition surgery offers a safe and effective treatment for infants with short-gut syndrome when medical management fails. Survivors achieved normal growth and development, tolerating regular diets.
Area of Science:
- Pediatric Surgery
- Gastroenterology
- Neonatology
Background:
- Short-gut syndrome necessitates extensive intestinal resection in infants.
- Medical management often proves refractory, leading to complications from total parenteral nutrition (TPN).
Purpose of the Study:
- To evaluate the safety and efficacy of isoperistaltic colon interposition in infants with medically refractory short-gut syndrome.
- To identify factors associated with successful outcomes following colon interposition.
Main Methods:
- Six infants with short-gut syndrome underwent isoperistaltic colon interposition after failed medical therapy.
- Patient data including reasons for resection, duration of medical therapy, and post-operative outcomes were analyzed.
Main Results:
- No perioperative mortality or morbidity was observed.
- Three infants were successfully weaned from TPN and survived, while three died from TPN complications.
- Long-term survival correlated with greater remaining small bowel length, younger age at surgery, and shorter duration of prior medical management.
Conclusions:
- Isoperistaltic colon interposition is a safe and effective adjuvant therapy for select infants with short-gut syndrome.
- Successful outcomes are linked to specific patient characteristics and surgical timing.
- Survivors demonstrated normal growth, development, and dietary tolerance.
Abstract:
Six infants with short-gut syndrome refractory to medical management underwent isoperistaltic colon interposition (length 11.7 +/- 3.1 cm.). The abdominal catastrophes that required extensive intestinal resection were: volvulus (3), necrotizing enterocolitis (2), and gastroschisis with intestinal atresia (1). No infant had another major congenital anomaly. The average trial of attempted medical therapy prior to colon interposition was 5.5 +/- 3.6 months. There was no perioperative mortality or morbidity associated with the colon interposition. Following the colon interposition, three infants were weaned from total parenteral nutrition (TPN) in 3 +/- 1 months and all survived. In contrast, three infants could not be withdrawn from TPN and they died secondary to complications of TPN (2 from sepsis and 1 from hepatic failure). Long-term survival was associated with a greater length of small bowel remaining after the initial resection (51 +/- 12 cm v 35 +/- 24 cm), colon interposition at a younger age (3 +/- 1 months v 8 +/- 3.5 months), and a shorter duration of medical management prior to colon interposition (2.8 +/- 0.8 months v 6.7 +/- 5.0 months). All survivors are now tolerating a regular diet and having one to four formed stools per day. Normal somatic growth and developmental milestones are being achieved. The follow-up period is from 24 to 84 months. Our experience with the colon interposition in the patient with short gut syndrome has led us to conclude that when a reasonable trial of medical management has failed, a colon interposition is a safe and effective adjuvant to treatment.